Bristol shares slipped less than 1 percent in Wednesday trade on the New York Stock Exchange.
The New York-based drugmaker raised its 2008 earnings forecast, excluding special items, to $1.65 to $1.75 per share, from a previous view of $1.60 to $1.70 per share.
It also increased its dividend by 11 percent, the first increase since 2002.
Bristol-Myers also plans to sell its medical imaging business and is reviewing strategic alternatives for its Convatec wound healing unit and Mead Johnson nutritionals unit.
The transactions would bring the company cash that could be plowed into its higher-profit core pharmaceuticals business.